Back to search results

Blood Test for Long COVID Identification

This study is testing a new blood test called "RNA Biomarker Blood Test" to help identify Long COVID. Researchers want to see if they can create a computer program (algorithm) that can classify specific RNA sequences in your blood to tell if you have Long COVID. You can join if you are 18 or older, have a confirmed past SARS-CoV-2 (COVID-19) infection, and are experiencing new, lasting symptoms related to it. The goal is to develop a reliable test to identify Long COVID and its severity. The study is currently unclear about its recruitment status.

Study design
This is an interventional study planning to enroll 224 participants. It aims to develop an algorithm to classify RNA sequences to identify Long COVID.
What's involved
You would be screened and provide two blood samples about 28 days apart. Based on survey results, you will be placed into one of fourteen groups reflecting your type of Long COVID.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, developing an algorithm to classify RNA sequences, is measured at 30 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06311435

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

Recruiting
NAAges 18+InterventionalDiagnostic
MaxWell Clinic, PLC
~224 participants
Updated 2024-10-18 on ClinicalTrials.gov
What's tested:RNA Biomarker Blood Test

At a glance

Recruiting sites
2 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Develop algorithm to classify RNA sequences to identify long COVID
Measured over 30 days

Conditions

Long COVID

Explore related trials

Post-Acute Sequelae of COVID-19

NCT06311435

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The MaxWell Clinic

    Brentwood, Tennesseestudy coordinator listed

    Recruiting

  • The MaxWell Clinic

    Brentwood, Tennesseestudy coordinator listed

    Recruiting

  • University of Iowa

    Iowa City, Iowastudy coordinator listed

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Justin Davis
[email protected]
615-370-0091
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Mentally capable of understanding and completing informed consent for the study.
Precipitants with a lab verified diagnosis of SARS-CoV-2 or clinician note/record that an appropriate rapid test for SARS-CoV-2 was positive.
To qualify for long COVID group participants will need to have new, persistent symptoms related to SARS-CoV-2 infection. iv. No one under the age of 18.

Exclusion

Subject is unable to provide informed consent.
Primary Investigator or Sub-Investigator determines the participant's ongoing medical complaints that began after 1 November 2019 are not related to SARS-COV-2 but another disease process.

What this trial measures

  • Develop algorithm to classify RNA sequences to identify long COVID30 days

    The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID